November 4, 2019 10:44 AM EST

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Amber Tong

In the latest boost for China’s flourishing antibody R&D scene, Merck-partnered Akesobio has bagged $150 million in Series D cash to push a slate of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data